Show simple item record

dc.contributor.authorJones, RL
dc.coverage.spatialEngland
dc.date.accessioned2022-11-30T11:42:58Z
dc.date.available2022-11-30T11:42:58Z
dc.date.issued2022-10-03
dc.identifier.citationFuture Oncology, 2022, 18 (29s), pp. 3 - 11en_US
dc.identifier.issn1479-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5587
dc.identifier.eissn1744-8301
dc.identifier.eissn1744-8301
dc.identifier.doi10.2217/fon-2022-0635
dc.description.abstractAn international collaborative project set up as a 'priority setting partnership' used a questionnaire to capture the views of patients, carers and clinicians about the sarcoma research agenda. Responses from 25 patients with leiomyosarcoma (LMS) in eight countries provided useful insight from the patient's perspective. Unmet needs identified by patients were in the areas of: LMS-specific trial design; exploring new therapeutic avenues; avoiding morcellation; exploring the immune system in LMS; investigating circulating tumor DNA; implementing molecular characterization of LMS; conducting basic research and a translational pipeline; evaluating imaging modalities; improving early diagnosis; identifying patient-reported outcomes; improving communication, information and support; and addressing survivorship and end-of-life care. Each of the unmet needs is described in more detail.
dc.formatPrint-Electronic
dc.format.extent3 - 11
dc.languageeng
dc.language.isoengen_US
dc.publisherFUTURE MEDICINE LTDen_US
dc.relation.ispartofFuture Oncology
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.subjectadvocacy
dc.subjectleiomyosarcoma
dc.subjectpatient perspective
dc.subjectunmet medical needs
dc.subjectFemale
dc.subjectHumans
dc.subjectCirculating Tumor DNA
dc.subjectLeiomyosarcoma
dc.subjectClinical Trials as Topic
dc.subjectResearch Design
dc.titleOn the road to improved outcomes by capturing leiomyosarcoma patients' views.en_US
dc.typeJournal Article
dcterms.dateAccepted2022-10-03
dc.date.updated2022-11-30T11:41:48Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.2217/fon-2022-0635en_US
rioxxterms.licenseref.startdate2022-10-03
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36189762
pubs.issue29s
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.2217/fon-2022-0635
pubs.volume18
dc.contributor.icrauthorJones, Robin
icr.provenanceDeposited by Mr Arek Surman on 2022-11-30. Deposit type is initial. No. of files: 1. Files: fon-2022-0635.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/